NYSE: NVS
Novartis is a pure-play innovative medicines company focused on the research, development, manufacturing, and commercialization of a broad range of pharmaceutical products. The company concentrates on four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience, and oncology, supplemented by an established brands portfolio. Novartis operates two established technology platforms (chemistry and biotherapeutics) and is investing in three emerging platforms: gene & cell therapy, radioligand therapy, and xRNA. Its medicines reach more than 300 million people worldwide. Key growth products include Kisqali (breast cancer), Kesimpta (multiple sclerosis), Pluvicto (prostate cancer radioligand therapy), Cosentyx (immunology), Entresto (heart failure/hypertension), Scemblix (chronic myeloid leukemia), and Leqvio (cholesterol-lowering siRNA therapy). The company has approximately 100 projects in clinical development and is geographically focused on growing in the US, China, Germany, and Japan. Novartis recently expanded into RNA therapeutics through its acquisition of Avidity Biosciences, adding capabilities targeting rare neuromuscular genetic disorders. The company operates as a single global operating segment and reports in US dollars. Updated
Markets are taking a beating as crude oil surges past $100 and Treasury yields hit multi-year highs, setting up a make-or-break inflation report that could seal the Fed's next move. Wall Street…
Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same…
Novartis just committed billions not to discover a new drug but to change how an existing one enters your body. The reason why that quiet engineering bet could matter more than a…
Omor Ibne Ehsan A clinical-stage radiopharmaceutical startup with no product revenue just caught the attention of three of pharma's biggest acquirers, and the rights structure hiding inside its Lilly partnership may explain exactly why.
Legend Biotech just posted a quarter that flipped a key narrative for LEGN shareholders, but with a CEO transition underway and the stock still down sharply over the past year, the real…
BioCryst just turned profitable, its HAE drug Orladeyo is minting cash, and a rival's blockbuster acquisition just put the whole rare-disease sector in play. So which pharma giant has the most to…
Replacing $19,000 in annual passive income from a $350,000 portfolio requires a blended yield of roughly 5.4%. That figure is nearly impossible to reach using only large-cap U.S. stocks, where the S&P…
Franklin FTSE International Low Volatility High Dividend Index ETF (NYSEARCA:LVHI) closed Friday at $41 after a quarterly distribution cycle that continues to deliver the income international dividend investors buy this fund for.…
VanEck Pharmaceutical ETF (NYSEARCA:PPH) exists to give investors broad exposure to the global pharmaceutical industry without the binary risk of betting on a single drug pipeline. Right now, that diversification is being…
Most income ETFs draw from a single well: either dividends or options premium. The Amplify CWP International Enhanced Dividend Income ETF (NYSEARCA:IDVO) draws from three simultaneously, and the way it selects holdings…
If a recession were to hit, it’s a foregone conclusion that people won’t stop taking their prescriptions, and they won’t cancel major medical treatments. The same can be said for people who…
AbbVie just rewarded its shareholders again with a dividend. This stock has boosted its payout annually for more than 50 years.
Here is an assessment of how safe the dividend at AbbVie appears to be based on a variety of metrics, including its status as a Dividend Aristocrat.
Fourth-quarter earnings kick off in a big way in 7 to 10 days, and earnings at some of the biggest and best U.S. companies are likely expected to decline for the third…
While many investment professionals suggest short Treasury paper and money markets, healthcare is the place in 2024 for long-term investors looking for growth and income. Demand is growing as the country ages;…
Novartis is a pure-play innovative medicines company focused on the research, development, manufacturing, and commercialization of a broad range of pharmaceutical products.
24/7 Wall St.'s 12-month price target for NVS is $161.35, rated Buy. The Wall Street consensus target is $156.29. NVS price prediction →
